Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + Chemotherapy
Phase 3Recruiting 2 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Trial Timeline
Feb 27, 2025 → Feb 1, 2030
NCT ID
NCT06731478About Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + Chemotherapy
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + Chemotherapy is a phase 3 stage product being developed by Daiichi Sankyo for Gastric Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06731478. Target conditions include Gastric Cancer, Gastroesophageal Junction Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06731478 | Phase 3 | Recruiting |
Competing Products
20 competing products in Gastric Cancer